Transition Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Transition Therapeutics Inc.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
How Boehringer Ingelheim Deepened Its Digital Transformation
While many pharma companies have integrated digital tools like cloud services into their operations, some are later adopters. Boehringer Ingelheim is one of the most recent companies to announce a move to a cloud-based R&D platform as part of the company’s commitment to digital transformation. For those still considering how to go about the shift to digital, rolling things out in the right order is one important factor, an EY expert tells In Vivo.
Money, Life And Pursuit Of Paxlovid: Behind China's Mania For Pfizer COVID Drug
From being little known to sought after by millions, Pfizer’s oral antiviral Paxlovid is fast becoming the most pursued medicine in China, amid the largest outbreak of COVID-19 infections the world has yet seen.
- Other Names / Subsidiaries
- Waratah Pharmaceuticals Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.